User:Mercy Mungai/sandbox
| Submission declined on 13 September 2024 by Liance (talk). The content of this submission includes material that does not meet Wikipedia's minimum standard for inline citations. Please cite your sources using footnotes. For instructions on how to do this, please see Referencing for beginners. Thank you. This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: "renowned", "recognized for pioneering", etc. needs to be rewritten to be more neutral... ~Liancetalk 14:01, 13 September 2024 (UTC)
Thomas Thum
Thomus Thum | |
|---|---|
| Born | 16 November 1974 (age 49) Hildesheim, Germany |
| Alma mater | Hannover Medical School |
| Awards | Julian-Desmond Award 2022 Paul-Martini Award 2021 |
| Scientific career | |
| Fields | Medicine, Cardiology |
| Institutions | Hannover Medical School Imperial College London |
Prof. Dr. med. PhD Thomas Thum is a renowned cardiologist and entrepreneur. He was born on 16th November 1974 in Hildesheim, Germany.
Early Life and Education
[edit]Prof. Thum attended Gymnasium Josephinum in Hildesheim. Thum completed his medical studies at Hannover Medical School between 1994 and 2001, where he also achieved his medical doctorate in 2001.[1]. Thum pursued further education by obtaining a PhD from the National Heart and Lung Institute at Imperial College London, under the supervision of Prof. Philip A. Poole-Wilson.[2]
Academic Career
[edit]In 2009, Thum became the Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School[3]. Since 2013, he serves as a visiting professor at the National Heart and Lung Institute at Imperial College London[4]. From 2021 to 2023, he was the Director of the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hannover.In addition to his academic roles, Prof. Thum has also worked at several prestigious institutions[5]. Between 2003 and 2004, he held a position in the Department of Clinical Pharmacology at Hannover Medical School and the Fraunhofer Institute of Toxicology and Experimental Medicine. He then served as a Resident Physician at the Julius-Maximilian-University Würzburg, specializing in internal medicine and cardiology[6]. From 2006 to 2009, Thum led a junior research group at the Interdisciplinary Center for Clinical Research (IZKF) in Würzburg, focusing on "Cardiac Wounding and Healing."
Prof. Thum excelled in the Board Examinations for Internal Medicine and Cardiology in 2009 and became full professor (W3) at Hannover Medical School, where he found the Institute of Molecular and Translational Therapeutic Strategies (IMTTS)[7]. He was also integrated into the Excellence Cluster REBIRTH on Regenerative Medicine and held leadership roles at the Integrated Research and Treatment Center Transplantation (IFB-Tx), focusing on improving transplant outcomes by addressing tissue fibrosis.
Entrepreneurial Ventures
[edit]In 2016, Thum founded Cardior Pharmaceuticals GmbH, a biotechnology company focused on noncoding RNA-based therapeutics for heart failure[8]. Under his leadership as Managing Director, Chief Scientific (CSO) and later Chief Medical Officer (CMO), Cardior raised about €80 million through multiple financing rounds. In May 2024, Novo Nordisk acquired Cardior Pharmaceuticals in a deal valued at up to €1.025 billion. The acquisition marked one of the largest exits in the European biotech industry[9]
Research Contributions and Innovation
[edit]Prof. Thum is recognized for pioneering oligonucleotide-based therapies for heart diseases, particularly in targeting microRNA-21 to combat cardiac fibrosis. His work on miRNA-21, published in Nature, demonstrated its therapeutic potential, inspiring numerous subsequent studies in fibrosis and heart disease[10].Additionally, his team identified the miRNA-212/132 cluster, which plays a key role in cardiac remodeling and autophagy[11]. He next translated these discoveries onto the first study testing an oligonucleotide inhibitor in heart failure patients that was published in 2021[12]. Currently following is a clinical phase 2 "HF-REVERT" trial to evaluate this therapy in post-myocardial infarction heart failure patients. Prof. Thum is frequently mentioned as Highly Cited Researcher by Claviate Analytics[13].Thum's recent research has focused on cardiovascular long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), which have potential as diagnostic and prognostic markers, as well as tailored therapeutic targets for cardiac diseases and beyond.
Awards and Recognition
[edit]Throughout his career, Thum has received numerous prestigious awards, including the Paul-Martini Award in 2021, the Desmond Julian Award in 2022, and the Sir Hans Krebs Award in 2014[14][15]. He was also awarded an ERC Advanced Grant in 2022, adding to his earlier ERC-funded projects, such as an ERC Consolidator Grant (2015) and ERC Proof of Concept Grant (2020).
Editorial Roles and Professional Memberships
[edit]Thum served on the editorial boards of major cardiovascular journals such as Circulation Research, European Heart Journal, and Cardiovascular Research. He has also served as a reviewer for funding bodies like the European Research Council and the British Heart Foundation.
Patents and Clinical Impact
[edit]Thum holds over 50 patents, many focused on anti-fibrotic therapies and heart failure treatments. His discoveries, including those targeting miRNAs, such as miR-21 and miR-132, as well as lncRNAs like H19 and Meg3, are patented and some are in clinical development, contributing to advancements in RNA-based cardiovascular therapies.
References
[edit]- ^ "Medizinische Hochschule Hannover : MHH". www.mhh.de. Retrieved 2024-09-13.
- ^ "National Heart and Lung Institute". Imperial College London. 2024-09-23. Retrieved 2024-09-13.
- ^ "Thomas Thum - Cardior Pharmaceuticals | RNA Leaders Europe Speaker". informaconnect.com. Retrieved 2024-09-13.
- ^ "National Heart and Lung Institute". Imperial College London. 2024-09-23. Retrieved 2024-09-13.
- ^ "Research Area Pharmaceutical Biotechnology in GERiT | DFG". gerit.org. Retrieved 2024-09-13.
- ^ "The University". www.uni-wuerzburg.de. Retrieved 2024-09-13.
- ^ "Medizinische Hochschule Hannover : IMTTS". www.mhh.de. Retrieved 2024-09-13.
- ^ "Home". Cardior. Retrieved 2024-09-13.
- ^ "Subscribe to read". www.ft.com. Retrieved 2024-09-13.
{{cite web}}: Cite uses generic title (help) - ^ Thum, Thomas; Gross, Carina; Fiedler, Jan; Fischer, Thomas; Kissler, Stephan; Bussen, Markus; Galuppo, Paolo; Just, Steffen; Rottbauer, Wolfgang; Frantz, Stefan; Castoldi, Mirco; Soutschek, Jürgen; Koteliansky, Victor; Rosenwald, Andreas; Basson, M. Albert (2008-12). "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts". Nature. 456 (7224): 980–984. doi:10.1038/nature07511. ISSN 1476-4687.
{{cite journal}}: Check date values in:|date=(help) - ^ Ucar, Ahmet; Gupta, Shashi K.; Fiedler, Jan; Erikci, Erdem; Kardasinski, Michal; Batkai, Sandor; Dangwal, Seema; Kumarswamy, Regalla; Bang, Claudia; Holzmann, Angelika; Remke, Janet; Caprio, Massimiliano; Jentzsch, Claudia; Engelhardt, Stefan; Geisendorf, Sabine (2012-09-25). "The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy". Nature Communications. 3 (1): 1078. doi:10.1038/ncomms2090. ISSN 2041-1723.
- ^ academic.oup.com https://academic.oup.com/eurheartj/article/42/2/178/5974817. Retrieved 2024-09-13.
{{cite web}}: Missing or empty|title=(help) - ^ "Medizinische Hochschule Hannover : MHH researchers highly regarded". www.mhh.de. Retrieved 2024-09-13.
- ^ "Paul-Martini-Stiftung". www.paul-martini-stiftung.de. Retrieved 2024-09-13.
- ^ European Society of Cardiology. "Sir Hans Krebs Award".